BiotechTube

Symbicort® total dose 400ug/12ug + Symbicort® total dose 800ug/24ug + Formoterol 24ug + BUD total dose 800ug

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Chronic Obstructive Lung Disease

Conditions

Chronic Obstructive Lung Disease

Trial Timeline

Jan 1, 2013 → Apr 1, 2015

NCT ID
NCT01787097

About Symbicort® total dose 400ug/12ug + Symbicort® total dose 800ug/24ug + Formoterol 24ug + BUD total dose 800ug

Symbicort® total dose 400ug/12ug + Symbicort® total dose 800ug/24ug + Formoterol 24ug + BUD total dose 800ug is a approved stage product being developed by AstraZeneca for Chronic Obstructive Lung Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01787097. Target conditions include Chronic Obstructive Lung Disease.

What happened to similar drugs?

20 of 20 similar drugs in Chronic Obstructive Lung Disease were approved

Approved (20) Terminated (3) Active (0)
✅Pegasys® + Pegasys®Chugai PharmaceuticalApproved
✅Telmisartan/Rosuvastatin 40/10mg + Telmisartan 40mgYuhanApproved
✅placebo + aspirin + clopidogrel + aspirin OR prasugrel + aspirinDaiichi SankyoApproved
✅alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
✅alefaceptAstellas PharmaApproved
✅AlefaceptAstellas PharmaApproved
✅lysozyme 90 mg + PlaceboEisaiApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01787097ApprovedCompleted

Competing Products

20 competing products in Chronic Obstructive Lung Disease

See all competitors
ProductCompanyStageHype Score
macitentan 10 mgBML, Inc.Phase 3
32
KPL-716 + PlaceboKiniksa PharmaceuticalsPhase 2
29
TERN-701Terns PharmaceuticalsPhase 1/2
36
Fludarabine + Cyclophosphamide + PRGN-3007PrecigenPhase 1
23
LY3556050 + PlaceboEli LillyPhase 2
35
THB001Third Harmonic BioPhase 1
11
BriquilimabJasper TherapeuticsPhase 1/2
26
BriquilimabJasper TherapeuticsPhase 1/2
14
BriquilimabJasper TherapeuticsPhase 2
29
Empagliflozin + Matching placeboEli LillyPhase 3
40
LY3461767 + PlaceboEli LillyPhase 1
29
Pirtobrutinib + Venetoclax + RituximabEli LillyPhase 3
44
LY3526318 + PlaceboEli LillyPhase 2
35
PirtobrutinibEli LillyPhase 2
42
Ibrutinib + LY3214996Eli LillyPhase 1
21
Pirtobrutinib + AcalabrutinibEli LillyPhase 2
27
LYR-210Lyra TherapeuticsPhase 2
25
LYR-220 Design 1 (Part 1 only) + LYR-220 Design 2 (Part 1 and Part 2) + Bilateral sham procedure control (Part 2)Lyra TherapeuticsPhase 2
25
480 Mometasone Furoate Sinus Drug DepotLyra TherapeuticsPhase 1
19
LYR-210 + Sham procedure controlLyra TherapeuticsPhase 3
30